OPTN OptiNose

Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco

Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco

YARDLEY, Pa., Feb. 15, 2019 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will present clinical and health economic outcomes data at the 2019 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Francisco, California, February 22 - 25, 2019. Abstracts are available on the AAAAI Annual Meeting website located at . XHANCE® (fluticasone propionate) nasal spray, 93 mcg, is approved by the U.S. Food and Drug Administration for the treatment of nasal polyps in patients 18 years of age or older. 

Data on XHANCE, trade name for the Exhalation Delivery System with fluticasone (EDS-FLU), is expected to be highlighted in four scientific posters presented during the AAAAI Annual Meeting:

Poster Session #2213 is scheduled on Saturday, February 23 from 9:45 a.m. to 10:45 a.m. in the Moscone Center South, Hall B.

  • Poster 190: Exhalation Delivery System (EDS) Intranasal Steroid vs Conventional Inhaled Nasal Steroids (INS): Patient Preference, Comfort and Ease of Use  

Poster Session #4210 is scheduled on Monday, February 25 from 9:45 a.m. to 10:45 a.m. in the Moscone Center South, Hall B.

  • Poster 853: Lifetime Work Productivity Gains Among Patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) Treated with EDS-FLU

Poster Session #4212 is scheduled on Monday, February 25 from 9:45 a.m. to 10:45 a.m. in the Moscone Center South, Hall B.

  • Poster 858: Evidence is Limited for the Efficacy and Safety of Corticosteroid Irrigation in Chronic Rhinosinusitis (CRS)
  • Poster 859: Evidence for Twice-Daily Nasal Steroids Versus Once Daily for Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

The poster presentations are intended for scientific discussion only.

About Optinose

Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit  or follow us on and .

Optinose Investor Contact

Jonathan Neely

267.521.0531

EN
15/02/2019

Underlying

OPTNOptiNose

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptiNose

 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results a...

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended Dece...

March 26, 2025 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceut...

March 20, 2025 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Announces Reporting Date for Fourth Quarter and Full Year 202...

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern Time YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter and full year of 2024 and corporate updates, before market open, on Thursday, March 20, 2025. Company to Host Conference CallMembers of the Company’s leadership team w...

March 11, 2025 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Ne...

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary unaudited XHANCE® (fluticasone propionate) net product revenue of $22.4 million for the three months ended December 31, 2024. “Our preliminary unaudited fourth quarter n...

January 15, 2025 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Announces 1-for-15 Reverse Stock Split

Optinose Announces 1-for-15 Reverse Stock Split YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose’s common stock will trade on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis under a new CUSIP number 68404V209 and Optinose’s existing trading s...

December 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch